Assessing Lepu Biopharma (SEHK:2157) Valuation After Its Earnings Turnaround And Recent Share Price Strength

Simply Wall St.03-28

Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier. See our latest analysis ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622800406?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-28 12:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622800406","market":"hk","top_or_hot":-1,"title":"Assessing Lepu Biopharma (SEHK:2157) Valuation After Its Earnings Turnaround And Recent Share Price Strength","media":"Simply Wall St.","content":"<div>\n<p>Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier. See our latest analysis ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Lepu Biopharma (SEHK:2157) Valuation After Its Earnings Turnaround And Recent Share Price Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Lepu Biopharma (SEHK:2157) Valuation After Its Earnings Turnaround And Recent Share Price Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-28 12:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier. See our latest analysis ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin","article_id":"2622800406","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharma-sehk2157-valuation-after-its-earnin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622800406","pubTimestamp":1774671667,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier.\nSee our latest analysis for Lepu Biopharma.\nThe earnings swing appears to be feeding into sentiment, with the HK$5.6 share price sitting after an 8.74% 1 day share price return, a 22.81% 30 day share price return and a 46.98% 1 year total shareholder return. This suggests that momentum has been building recently.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物-B"},"translate_title":"评估乐普生物制药（SEHK：2157）盈利好转和近期股价走强后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"Lepu Biopharma (SEHK:2157) just reported full year 2025 earnings, with sales of CN¥934.87 million and net income of CN¥261.36 million, compared with a net loss a year earlier. See our latest analysis for Lepu Biopharma. The earnings swing appears to be feeding into sentiment, with the HK$5.6 share price sitting after an 8.74% 1 day share price return, a 22.81% 30 day share price return and a 46.98% 1 year total shareholder return. This suggests that momentum has been building recently. If this kind of move has you looking for other ideas in healthcare and biotech, it could be worth scanning a focused list of 124 healthcare AI stocks as a next step. With Lepu Biopharma now profitable and the share price already up strongly over the past year, the key question is whether the recent earnings shift is fully reflected in the valuation or whether markets are still underestimating the company’s prospects. AdvertisementPreferred P/E of 34.1x: Is it justified? Lepu Biopharma trades on a P/E of 34.1x, and at a last close of HK$5.6 the valuation sits below the peer average multiple but above its estimated fair level. The P/E ratio compares the share price with earnings per share. For a company like Lepu Biopharma it reflects what investors are currently willing to pay for each unit of profit in a higher risk, research heavy biotech space. Here, the 34.1x P/E is described as good value compared with both the Asian biotechs average of 37.1x and the peer average of 51.3x. However, it is also flagged as expensive versus an estimated fair P/E of 4.1x, a level the market could eventually move closer to if expectations reset. Explore the SWS fair ratio for Lepu Biopharma Result: Price-to-earnings of 34.1x (OVERVALUED) However, there are clear risks, including the high 34.1x P/E if sentiment cools, as well as the possibility that key oncology drug trials or approvals disappoint expectations. Find out about the key risks to this Lepu Biopharma narrative. Next Steps With sentiment clearly mixed, given both the new profitability and the valuation concern, it makes sense to review the full picture yourself and be ready to respond promptly if it changes, starting with the 2 key rewards and 1 important warning sign Looking for more investment ideas? Do not stop with a single stock story. Broaden your watchlist with targeted ideas so you are ready when the next opportunity lines up with your approach.  Spot potential turnaround stories early by scanning 231 elite penny stocks with strong financials that already show stronger balance sheets and clearer business models than typical micro caps. Strengthen the core of your portfolio by reviewing 238 high quality undervalued stocks where solid fundamentals and pricing appear out of sync. Reduce portfolio stress by checking 281 resilient stocks with low risk scores that combine resilient financial profiles with more measured risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622800406","isCrawlerRequest":true}